ApeX Therapeutics (United States)

Recent papers from ApeX Therapeutics (United States)

1. Molecular Glue Degraders Enhance CAPRIN1‐Dependent Lysosomal Degradation of APP and Reduce Amyloid β in Alzheimer's DiseaseAdvanced Science · 2026
2. Abstract 7140: Synthetic lethality of Hsp90beta-selective inhibition with PARPi in homologous recombination repair proficient ovarian cancerCancer Research · 2026
3. Abstract 3053: Combination of the MDM2 antagonist ASTX295 and Olaparib as a novel treatment option for BRCA2 mutant, TP53 wild-type solid tumorsCancer Research · 2026
4. ISL1: A Novel Neuroendocrine Subtype in Small Cell Lung Cancer Predicts Durable Response to LurbinectedinMolecular Cancer Therapeutics · 2026
5. A phase I study targeting the APE1/Ref-1 redox signaling protein with APX3330: first clinical agent targeting APE1/Ref-1 in cancerThe Oncologist · 2025
6. New Ref-1/APE1 targeted inhibitors demonstrating improved potency for clinical applications in multiple cancer typesPharmacological Research · 2024
7. Bridging population pharmacokinetic and semimechanistic absorption modeling of APX3330CPT Pharmacometrics & Systems Pharmacology · 2023
8. A trispecific Ab directed to HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections2022
9. Ubiquitination and degradation of SUMO1 by small-molecule degraders extends survival of mice with patient-derived tumorsScience Translational Medicine · 2021
10. Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate CancerClinical Cancer Research · 2019
11. Ref-1/APE1 inhibition with novel small molecules blocks ocular neovascularization2018
12. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA MutationsClinical Cancer Research · 2018
13. Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trialsSHILAP Revista de lepidopterología · 2017
14. Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinicSHILAP Revista de lepidopterología · 2017
15. A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK StudyClinical Cancer Research · 2014
16. Single-Molecule Dynamics of Lysozyme Processing Distinguishes Linear and Cross-Linked Peptidoglycan SubstratesJournal of the American Chemical Society · 2012